Skip to content
Search

Latest Stories

BREAKING: Boots will cut more than 4,000 jobs, but plans exclude pharmacists

Boots has announced that it's planning to cut more than 4,000 jobs as part of a major shake-up to mitigate the "significant impact" of Covid-19.

A spokesperson for Boots UK told Pharmacy Business this lunchtime (July 9) that the "proposals are not expected to impact Boots pharmacists or pharmacy advisors."


The latest restructuring will affect around seven per cent of the company's workforce and will particularly affect staff at its head office in Nottingham.

The latest announcement comes after retail sales of Boots UK fell by 48 per cent over the past three months, while its opticians' business saw sales nosedive by 72 per cent compared to the same quarter last year, which is why the company is proposing to close 48 Boots Opticians stores.

Boots UK, which is owned by US-headquartered Walgreens Boots Alliance, said the cuts represented an "acceleration" of its transformation plans to improve profitability across the business.

Sebastian James, managing director of Boots UK, said: "The proposals announced today are decisive actions to accelerate our transformation plan, allow Boots to continue its vital role as part of the UK health system, and ensure profitable long-term growth.

"I am so very grateful to all our colleagues for their dedication during the last few challenging months. They have stepped forward to support their communities, our customers and the NHS during this time, and I am extremely proud to be serving alongside them."

"In doing this, we are building a stronger and more modern Boots for our customers, patients and colleagues.

"We recognise that today's proposals will be very difficult for the remarkable people who make up the heart of our business, and we will do everything in our power to provide the fullest support during this time."

Allaying fears, the company said its pharmacies continued to serve at the heart of communities across the UK, and its patient and customer satisfaction scores were at the highest levels ever.

With further investment in digital and online pharmacy and retail services, Boots hopes to provide new ways for patients to receive even more access to its trusted pharmacy care and advice.

More For You

Walgreens Boots Alliance acquired by Sycamore in deal

Walgreens Boots Alliancehas entered into “a definitive agreement” to be acquired by Sycamore Partners

Gettyimages

Walgreens Boots Alliance acquired by Sycamore in £18.3 billion deal

Walgreens Boots Alliance(WBA) has entered into “a definitive agreement” to be acquired by Sycamore Partners, a private equity firm specializing in retail, consumer and distribution-related investments.

“The total value of the transaction represents up to $23.7 billion (£18.3 billion),” the company announced late last night (6).

Keep ReadingShow less
Professor Sir Stephen Powis at a press briefing

Professor Sir Stephen Powis, was appointed national medical director of NHS England in 2018

NHS

NHS England’s top doctor to step down following Amanda Pritchard’s resignation

Just a week after NHS England chief executive Amanda Pritchard announced her resignation, the organisation’s national medical director, Professor Sir Stephen Powis, has confirmed he will step down this summer after more than seven years in the role.

In a statement released on Thursday, Professor Powis revealed that he had informed Pritchard of his intention to leave in a letter back in January.

Keep ReadingShow less
PDA calls on GP practices to use funding boost to improve job security for pharmacists

Now, it is time to focus on the community pharmacy contract

gettyimages

PDA urges GP practices to ensure funding boost supports employed pharmacists

The Pharmacists' Defence Association (PDA) has called on GP practicesto ensure that all healthcare professionals they employ, including pharmacists, benefit from the 7.2% funding boost they received under a newly agreed contract.

GP employers are encouraged to improve “job security, pay and conditions” for employees with this increased funding.

Keep ReadingShow less
Fourth Shift: Investment in Innovative Medicines Crucial for NHS 10-Year Plan Success

Medicines should be viewed as an investment rather than a cost

gettyimages

ABPI wants to see a ‘fourth shift’ in NHS 10-Year Health Plan


The Association of the British Pharmaceutical Industry (ABPI) has called on the government to increase investment in innovative medicines and vaccines, describing it as a crucial “fourth shift” necessary to ensure the NHS is fit for the future.

Keep ReadingShow less
Lawrence Tallon named new MHRA chief executive

Lawrence Tallon

Photo credit: Sciana Network

Lawrence Tallon named new MHRA chief executive

Lawrence Tallon has been appointed as the new chief executive officer of the Medicines and Healthcare products Regulatory Agency (MHRA), effective 1 April 2025.

He will succeed Dame June Raine DBE, who is retiring after leading the agency since 2019.

Keep ReadingShow less